candesartan has been researched along with Ischemia in 6 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neurovascular protection against cerebral ischemia is not consistently observed with a postischemia hypotensive dose of candesartan." | 7.77 | Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia. ( Fu, H; Hosomi, N; Itano, T; Kohno, M; Liu, G; Masugata, H; Matsumoto, M; Miki, T; Nakano, D; Nishiyama, A; Pelisch, N; Sueda, Y; Ueno, M, 2011) |
| "Candesartan treatment (10 or 30 mg/kg; orally) was initiated one day post CLI and thereafter once daily for up to 14 days." | 5.91 | Candesartan protects against unilateral peripheral limb ischemia in type-2 diabetic rats: Possible contribution of PI3K-Akt-eNOS-VEGF angiogenic signaling pathway. ( Abdelaziz, RR; Elshaer, SL; Khaled, S; Suddek, GM, 2023) |
| "Neurovascular protection against cerebral ischemia is not consistently observed with a postischemia hypotensive dose of candesartan." | 3.77 | Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia. ( Fu, H; Hosomi, N; Itano, T; Kohno, M; Liu, G; Masugata, H; Matsumoto, M; Miki, T; Nakano, D; Nishiyama, A; Pelisch, N; Sueda, Y; Ueno, M, 2011) |
| "Candesartan treatment (10 or 30 mg/kg; orally) was initiated one day post CLI and thereafter once daily for up to 14 days." | 1.91 | Candesartan protects against unilateral peripheral limb ischemia in type-2 diabetic rats: Possible contribution of PI3K-Akt-eNOS-VEGF angiogenic signaling pathway. ( Abdelaziz, RR; Elshaer, SL; Khaled, S; Suddek, GM, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Khaled, S | 1 |
| Abdelaziz, RR | 1 |
| Suddek, GM | 1 |
| Elshaer, SL | 2 |
| Shanab, AY | 1 |
| El-Azab, MF | 1 |
| Soliman, S | 1 |
| Sabbineni, H | 1 |
| Matragoon, S | 1 |
| Fagan, SC | 1 |
| El-Remessy, AB | 1 |
| Hoshide, S | 1 |
| Kario, K | 1 |
| Shimada, K | 1 |
| Fu, H | 1 |
| Hosomi, N | 1 |
| Pelisch, N | 1 |
| Nakano, D | 1 |
| Liu, G | 1 |
| Ueno, M | 1 |
| Miki, T | 1 |
| Masugata, H | 1 |
| Sueda, Y | 1 |
| Itano, T | 1 |
| Matsumoto, M | 1 |
| Nishiyama, A | 1 |
| Kohno, M | 1 |
| Goykhman, P | 1 |
| Mehta, PK | 1 |
| Minissian, M | 1 |
| Thomson, LE | 1 |
| Berman, DS | 1 |
| Ishimori, ML | 1 |
| Wallace, DJ | 1 |
| Weisman, MH | 1 |
| Shufelt, CL | 1 |
| Bairey Merz, CN | 1 |
| Masuko, H | 1 |
| Jin, MB | 1 |
| Horiuchi, H | 1 |
| Suzuki, T | 1 |
| Taniguchi, M | 1 |
| Shimamura, T | 1 |
| Fukai, M | 1 |
| Magata, S | 1 |
| Ogata, K | 1 |
| Ishikawa, H | 1 |
| Fujita, M | 1 |
| Nagashima, K | 1 |
| Furukawa, H | 1 |
| Todo, S | 1 |
6 other studies available for candesartan and Ischemia
| Article | Year |
|---|---|
Candesartan protects against unilateral peripheral limb ischemia in type-2 diabetic rats: Possible contribution of PI3K-Akt-eNOS-VEGF angiogenic signaling pathway.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Ischemia; Neovascularization, P | 2023 |
Candesartan stimulates reparative angiogenesis in ischemic retinopathy model: role of hemeoxygenase-1 (HO-1).
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Gene Silencing | 2015 |
Ischemic nephropathy in an elderly patient.
Topics: Aged; Antihypertensive Agents; Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Female; Humans; | 2008 |
Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Benzimidazoles; B | 2011 |
Subendocardial ischemia and myocarditis in systemic lupus erythematosus detected by cardiac magnetic resonance imaging.
Topics: Anti-Inflammatory Agents; Benzimidazoles; Biphenyl Compounds; Chest Pain; Coronary Angiography; Coro | 2012 |
Protective effect of agiotensin II type I receptor antagonist, CV-11974, on ischemia and reperfusion injury of the liver.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aspartate Aminotransferases; Benzimidazol | 2001 |